FeaturedNeurologyNeuroscience·April 20, 2023·6 min readCommon Sleeping Pill Could Slow or Stop Alzheimer’s DiseaseSuvorexant, a dual orexin receptor antagonist commonly prescribed to help treat insomnia reduced levels of the Alzheimer's-associated amyloid beta protein in the brain. The findings hint that the sleep medication could slow or stop Alzheimer's disease, but researchers say more research is needed to confirm the viability of the approach.Read More
FeaturedNeurologyNeuroscienceOpen Neuroscience Articles·April 1, 2023·4 min readStudy Supports Amyloid Hypothesis for Alzheimer’s but Suggests Alternative TreatmentA new study provides additional evidence for the "amyloid hypothesis" of Alzheimer's disease, reporting amyloid beta sparks an alliance between two proteins in neurons. This pairing is linked to half of the gene changes associated with Alzheimer's disease.Read More
FeaturedNeurologyNeuroscience·March 28, 2023·6 min readIndividualized Brain Fingerprints Can Help to Uncover Early Signs of Alzheimer’s DiseaseA novel neuroimaging technique allows physicians to visualize subtle brain changes on an individualized level in patients with pre-clinical Alzheimer's disease.Read More
FeaturedNeurologyNeuroscience·March 8, 2023·4 min readMIND and Mediterranean Diets Associated With Fewer Alzheimer’s Plaques and TanglesPeople who follow diets rich in leafy greens, olive oil, nuts, and fish, such as the MIND or Mediterranean diet, have fewer amyloid plaques and Tau tangles in their brains than those who follow a more conventional diet.Read More
FeaturedNeurologyNeuroscience·February 17, 2023·4 min readAlcohol Consumption Linked to Acceleration of Alzheimer’s DiseaseEven modest consumption of alcohol can accelerate brain atrophy and increase amyloid plaque formation. The findings reveal alcohol consumption can accelerate Alzheimer's disease pathologies.Read More
FeaturedNeurologyNeuroscience·February 6, 2023·5 min readPromising Treatment for Alzheimer’s DiseaseUsing theranostics to pinpoint and treat the earliest, preclinical symptoms of Alzheimer's disease, researchers say their new method shows promise in stopping the progression of Alzheimer's pathologies before the onset of irreversible neural damage.Read More
FeaturedNeurologyNeuroscience·February 2, 2023·6 min readBrain Cell Changes in Alzheimer’s Disease MappedA new method dubbed STARmap PLUS was utilized to track and map changes in tau and amyloid beta in the brain as Alzheimer's disease progressed in mouse models.Read More
FeaturedNeurologyNeuroscience·January 31, 2023·3 min readObesity-Related Neurodegeneration Mimics Alzheimer’s DiseaseResearchers discovered a correlation between obesity-related neurodegeneration and Alzheimer's disease pathology. Losing weight, they say, can slow age-related cognitive decline and reduce the risk of developing Alzheimer's.Read More
FeaturedNeurologyNeuroscience·January 26, 2023·5 min readProtein Plaques Associated With Disease Are Stickier Than ThoughtStudy provides experimental evidence of an alternative binding site on amyloid-beta aggregates. The discovery opens the door to the development of new therapies for Alzheimer's disease.Read More
FeaturedNeurologyNeuroscience·January 13, 2023·3 min readAccumulation of Amyloid Beta Protein at Sites of Potassium Depletion in the Brain DiscoveredSamples of brain tissue from those with Alzheimer's revealed marked changes in potassium isotopes that correlated with amyloid-beta accumulation.Read More
FeaturedNeurologyNeuroscience·January 6, 2023·4 min readNew Study Challenges Previous Ideas Regarding Alzheimer’s DiseaseThe brains of older, cognitively healthy people have similar amounts of dissolvable, non-fibrilla amyloid proteins as the brains of those with Alzheimer's disease. Findings challenge the long-standing theory that having higher levels of amyloid proteins is an underlying cause of Alzheimer's disease.Read More
FeaturedNeurologyNeuroscience·November 30, 2022·4 min readAlzheimer’s Amyloid-Clearing Monoclonal Antibody Drug Lecanemab Shows Positive Results, Poised for FDA ApprovalLecanemab, an amyloid-clearing monoclonal antibody drug shows positive results in the treatment of Alzheimer's disease. The drug is now poised for FDA approval early in 2023. Lecanemab slows cognitive decline by 27%.Read More
